Lyell Immunopharma (LYEL) EBITDA Margin Growth (3y) (2023 - 2026)
Lyell Immunopharma (LYEL) EBITDA Margin Growth (3y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 9,942.00 |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 530.00 |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | -1,211.00 |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 7,794.00 |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Lyell Immunopharma | 276.08 Mn | 276.08 Mn | - | -211.68 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -211.68 Mn |
| Dec 31, 2025 | -212.74 Mn |
| Sep 30, 2025 | 196.62 Mn |
| Jun 30, 2025 | -58.91 Mn |
| Mar 31, 2025 | -80.71 Mn |
| Dec 31, 2024 | -182.69 Mn |
| Sep 30, 2024 | -14.68 Mn |
| Jun 30, 2024 | -39.40 Mn |
| Mar 31, 2024 | -185.02 Mn |
| Dec 31, 2023 | -45.60 Mn |
| Sep 30, 2023 | -23.27 Mn |
| Jun 30, 2023 | -24.08 Mn |